INTRODUCTION
Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB), is arguably one of the most successful of all human pathogens. Within recorded history, it is likely the leading cause of death in Europe and the United States (Bloom and Murray, 1992) . Although the advent of modern diagnostics, antibacterials, and hygiene have dramatically reduced the death rate from TB in developed nations, MTB still caused 1.3 million deaths worldwide in 2012 (Zumla et al., 2013 )-more than from any other single bacterial pathogen (Nathan et al., 2008) .
Currently, ''short course'' therapy for TB consists of four drugs-isoniazid, rifampicin, ethambutol, and pyrazinamidethat are administered for 2 months, followed by 4 months of isoniazid and rifampicin (Plorde, 2004) . Although highly effective if taken to completion, this regimen is lengthy, poorly tolerated, and incompatible with many other medications, including some antiretrovirals prescribed for the treatment of HIV. Unfortunately, these issues have frequently led to low rates of completion for the full course of treatment (Gough and Kaufman, 2011) . The recent emergence of multidrug-resistant, extensively drugresistant, and totally drug-resistant tuberculosis strains further challenges the utility of the current front-line regimen (Babu and Laxminarayan, 2012; Gandhi et al., 2006; Velayati et al., 2009 ), which has not changed since the inclusion of rifampicin in 1965 (Williams and Duncan, 2007) .
New drugs to treat TB are desperately needed. Ideally, any new TB drugs would be active following oral administration, exhibit minimal side effects, be compatible with anti-retroviral treatments, have activity against strains resistant to other TB drugs, rapidly clear latent infections, and have pharmacokinetic and pharmacodynamic properties amenable to relatively infrequent dosing.
Antifolates, which interrupt the production of reduced folate cofactors, are one class of antibacterials with potential to meet this need (Figure 1 ). Reduced folate cofactors are used as one-carbon donors in a wide variety of essential cellular processes, including the biosynthesis of methionine, serine, and glycine; purine production; the conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (dTMP); and the formation of formyl-methionyl tRNAs in bacteria (Kompis et al., 2005) . Verified drug targets within the folate pathway include dihydropteroate synthase (DHPS) in bacteria and dihydrofolate reductase (DHFR) in bacteria, parasites, and mammals (Hirsch, 1942; Kompis et al., 2005; Potts et al., 2005) .
As early as 1940, promin, a pro-drug of the DHPS inhibitor dapsone (DDS), was shown to clear MTB infection in guinea pigs (Barr, 2011) . A current second-line therapy for TB, paraamino salicylic acid (PAS), is also a pro-drug substrate of DHPS that subsequently poisons as-yet unidentified downstream reactions (Chakraborty et al., 2013) . Another DHPS inhibitor, sulfamethoxazole (SMX), is active against MTB in vitro, with 90% growth inhibition at 8 mg/ml (Wallace et al., 1986) . The MTB DHFR enzyme, encoded by the gene dfrA, is exquisitely sensitive to the inhibitor methotrexate, but whole-cell MTB is resistant to killing by this drug (Kumar et al., 2012) . WR99210, another inhibitor of DHFR, was shown to have bactericidal activity against whole-cell MTB at 1 mM (Gerum et al., 2002) . Additionally, it has recently been demonstrated that a combination of the DHFR inhibitor trimethoprim and sulfamethoxazole maintains its activity in culture against some MDR-TB strains (Vilchè ze and Jacobs, 2012). However, there are currently no DHFR inhibitors used clinically for the treatment of TB.
Structural studies on MTB DHFR have revealed a general fold similar to the human ortholog, as well as features within the active site and potential conformational changes that are specific to MTB (Dias et al., 2014; Li et al., 2000) . The possibility of exploiting unique active site binding, combined with the demonstrated susceptibility of whole-cell MTB to inhibition by WR99210, inspired further work to develop antifolates with activity against MTB. We recently reported a high-throughput screen for inhibitors of the MTB DHFR enzyme (Kumar et al., 2012). Here we report the synthesis and characterization of methotrexate derivatives (Figure 1 ) with activity against MTB. In addition, we describe the molecular consequences associated with folate pathway disruption in MTB. Unlike the ''thymineless death'' associated with folate pathway inhibition in many other organisms, we find that MTB undergoes specific perturbation in reactions that produce and utilize S-adenosylmethionine, collectively known as the activated methyl cycle (Halliday et al., 2010; Parveen and Cornell, 2011) .
RESULTS

MTB Strains with Altered dfrA Expression
To differentiate between compounds targeting DHFR and those aimed at other targets, we created strains with altered expression of dfrA. H37Rv::pMRN1 has two copies of dfrA, resulting in overexpression of the cognate mRNA. The second copy was introduced via the integrating plasmid pMRN1, which contains the MTB dfrA sequence driven by the high-level constitutive MOP promoter. Transformants were identified using kanamycin selection and nearly 8-fold dfrA overexpression was confirmed via quantitative RT-PCR (qRT-PCR) (data not shown). We also created H37Rv:dfrA-TetON, in which the native dfrA promoter was swapped for an artificial promoter responsive to tetracycline. In the absence of tetracycline, expression of dfrA is approximately 30% of wild-type levels (Kumar et al., 2012 ). An anti-DHFR antibody was not available to determine the degree of altered expression at the protein level, but the results below strongly suggest that DHFR levels are in fact altered as expected in these strains.
WR99210 Targets MTB DHFR
Previously published studies have demonstrated not only that the triazine antimalarial WR99210 binds to and inhibits the MTB DHFR enzyme, but also that it inhibits the growth of MTB at approximately 1 mM (Gerum et al., 2002; Li et al., 2000) . However, the unusually low rate of resistant mutants (<1.2 3 10 À10 ) suggested that WR99210 might have multipleor off-target effects in MTB (Gerum et al., 2002) . To confirm that the observed activity of WR99210 resulted from inhibition of DHFR, minimum inhibitory concentrations (MICs) were compared between wild-type H37Rv and the dfrA over-and underexpressor strains. The MICs increased in the overexpressor and decreased in the underexpressor, showing that sensitivity to WR99210 is materially linked with intracellular levels of DHFR (Table 1) .
Test Compounds Exhibit Activity against H37Rv
To evaluate the susceptibility of MTB to antifolates, select compounds were assayed for their ability to inhibit growth of the wild-type MTB strain H37Rv (Table 1) . These compounds included commercially available antifolates, as well as methotrexate analogs that to the best of our knowledge have not previously been tested against MTB. Of the commercially available antifolates tested, piritrexim and trimetrexate both showed activity targeting the folate pathway, as evidenced by potent inhibition of the MTB DHFR enzyme in vitro and the shift in MIC in the DHFR overexpressor strain (Table 1) . As expected, methotrexate and trimethoprim showed no activity against wholecell MTB. Although trimethoprim's lack of whole-cell activity may be attributed to its relatively poor inhibition of DHFR (IC 50 = 19 mM), methotrexate is a potent DHFR inhibitor (IC 50 = 6.8 nM). Cognizant of previous efforts outside of the anti-infectives realm (Rosowsky 1973) , we also synthesized and tested analogs of methotrexate. We harnessed published chemical methods (Dawson et al., 1987; Piper and Montgomery, 1977; Rosowsky, 1973) to prepare the dimethyl (JSF-1187) and diethyl (JSF-1183) esters of methotrexate and demonstrated that they inhibit DHFR with IC 50 values of 50 and 30 nM, respectively. Unlike methotrexate, however, the esters also exhibited significant potency against whole-cell MTB (MIC = 600 nM for JSF-1183 and 200-400 nM for JSF-1187). Critically, the MIC values increased approximately two orders of magnitude when dfrA was overexpressed and decreased approximately 10-fold when dfrA expression was reduced (Table 1) . To investigate the active species within cells, we first measured intracellular compound levels by mass spectrometry and found a mixture of parent compound, each mono-ester, and some methotrexate (data not shown). We then synthesized and tested both mono-ethyl esters (JSF-2104 and JSF-2105) . Each of these compounds had weak but measurable activity on MTB, whereas neither showed improved activity on the DHFR enzyme (Table 1) .
WR99210 and JSF-1187 Are Effective against Clinical MTB Strains Isolated in 1905, H37Rv is a laboratory strain of MTB that retains full virulence in animal models (Cole et al., 1998) ; however, there are likely significant differences between currently circulating strains of MTB and H37Rv (Ioerger et al., 2010) . To test whether clinical strains might be similarly susceptible to growth inhibition by antifolates, a panel of five circulating MTB strains was treated with JSF-1187 and WR99210. All the strains tested were known to be pan-sensitive to current antitubercular drugs. Although there was some divergence in the observed MICs, all strains were susceptible to both WR99210 and JSF-1187 at levels similar to H37Rv (Table S1 available online). 
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Folate Pathway Disruption in M. tuberculosis DHFR and DHPS Inhibitors Are Synergistic in MTB In other systems, it is well established that the combination of DHFR and DHPS inhibitors can result in synergy that reduces the rate at which resistance develops while decreasing the total amount of drug that must be used, potentially minimizing the risk of unwanted side effects (Bushby, 1975) . To assess whether synergy also occurs in MTB, the DHFR inhibitors JSF-1187 and WR99210 were each combined with the DHPS inhibitors SMX (Wallace et al., 1986) and DDS (Karlson, 1963) . A traditional checkerboard titration format (Elion et al., 1954 ) was used to determine a fractional inhibitory concentration (FIC) for each set of compounds, where FIC is defined as the sum of the [concentration of each agent in combination]/[concentration of each agent individually] for both agents at a given level of inhibition. An FIC of 1 denotes an additive effect, whereas an FIC greater than 1 represents an antagonistic relationship and an FIC less than 1 represents a synergistic relationship between compounds. For all four compound combinations tested, the FIC was approximately 0.5, signifying synergy ( Figure 2 ). JSF-1187 and WR99210 were also tested for synergy with the antimycobacterials isoniazid, streptomycin, kanamycin, and rifampicin; additive relationships were observed for all such combinations (data not shown).
Exposure to Antifolates Leads to Downstream Metabolic Disruption
To probe the metabolic effects of these compounds in MTB, metabolite levels were quantified following treatment with WR99210 using LC-MS-based methods (de Carvalho et al., 2010b) . Cells were grown on nitrocellulose filters and exposed to drug at 0.8, 20, and 100 mM (approximately 0.253, 73, and 333 MIC) for 0, 4, and 24 hr. Cells were then rapidly quenched in a cold acetonitrile/methanol mixture and lysed. Ion profiles were generated and queried for 168 chromatographically resolved m/z species corresponding to known metabolites, of which 92 were detected (Table S2 ). For 80% of these peaks, there was little or no change in metabolite abundance following treatment. As expected, abundance of the m/z species corresponding to WR99210 increased with both time and concentration (data not shown). Increased WR99210 concentrations and longer exposure times were associated with increased metabolite dysregulation.
Twelve chromatographically resolved m/z species produced peaks whose relative abundance increased more than 2-fold in duplicate experiments, whereas six produced peaks whose relative abundance decreased more than 2-fold in both experiments (Table S2 ). Where available, we used coelution with chemical standards to confirm select metabolite identities and the method of standard addition to calculate metabolite concentrations. The largest increases were observed for 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and dUMP ($40-and 30-fold, respectively), and the largest decrease was for S-adenosylmethionine (SAM, at least 20-fold, to the limit of detection; Figure 3A ). Other metabolites (and/or their corresponding masses) that changed in concentration include homocysteine, S-ribosylhomocysteine, S-methylthioadenosine, lysine, serine, methionine, and uracil. The kinetics of metabolite disruption were also noteworthy ( Figure 3B ). Homocysteine levels increased within 4 hr, suggesting that reduced folate pools were already depleted. Methionine concentrations were halved at 4 hr but showed no change after that. In contrast, SAM levels were barely affected after 4 hr and then dropped substantially by 24 hr. At no time were significant changes in metabolite concentration observed for thymine, adenine, guanine, adenosine, or glycine.
In aggregate, exposure to WR99210 produced a striking pattern of metabolic disruption, with an emphasis on species associated with the active methyl cycle, reactions that produce or utilize S-adenosylmethionine. To assess which features of this pattern were shared by exposure to other antifolates, metabolomics experiments were also conducted with JSF-1183 and JSF-1187. MTB cells were grown on nitrocellulose filters, treated with 25 mM ($333 MIC) of each compound for 24 hr, and then processed for metabolomic analysis as above. Treatment with JSF-1183 or JSF-1187 each produced disruptions in core folate metabolites remarkably similar to those seen following exposure to WR99210. Key metabolites affected by WR99210 all trended in the same directions following treatment with JSF-1183 or JSF-1187. In particular, homocysteine and AICAR were highly induced, whereas SAM levels were highly depleted by all three drugs. The patterns were not absolutely identical; dUMP was more powerfully induced by WR99210, whereas methionine levels were decreased to a greater extent following treatment with JSF-1183 and JSF-1187. Such modest differences in metabolite levels following 24 hr of exposure to drugs are not surprising, and the overall pattern is similar enough to define a metabolic signature of antifolate inhibition in MTB. 
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Exposure to Antifolates Alters Expression of Genes within the Activated Methyl Cycle Microarray analysis was used to track mRNA levels following DHFR inhibition. Cultures were grown to early log phase (OD 600 = 0.1) and then exposed to WR99210, JSF-1183, or JSF-1187, each at $30 times the MIC, the highest concentration used for metabolomic analysis. 10 ml aliquots were taken before drug treatment and after 24 hr of exposure. The RNA was purified (A) WR99210 disrupts metabolite pools in a concentration-dependent fashion. Cells were treated for 24 hr with WR99210 at 0.8, 20, and 100 mM ($0.253, 73, and 333 MIC), and the data represent the fold change relative to time zero. (B) WR99210 disrupts metabolite pools in a time-dependent fashion. Conversion of homocysteine to methionine depends on the availability of reduced folate cofactors (indicated by red bars). Metabolites were identified by LC-MS (see Experimental Procedures), and putative metabolite identities were based on accurate mass (m/z) and chromatographic retention time matching. In most cases, metabolite identities were confirmed using chemical standards demonstrating coelution with experimental samples, and levels are expressed as the ratio of metabolite concentration compared to untreated cells. For AICAR, S-ribosylhomocysteine and S-methylthioadenosine, levels are expressed as the ratio of signal intensity compared to untreated cells. The results are representative of two independent experiments, with three technical replicates per experiment. S-Adenosylhomocysteine could not be detected in these experiments.
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Folate Pathway Disruption in M. tuberculosis from these samples and labeled with fluorescent probes, and then transcript abundance was quantified by hybridization to custom Nimblegen tiling arrays with 135,000 probes covering the MTB H37Rv genome (Minch et al., 2012) . Gene expression changes were considered significant if they produced a moderated t test p < 0.01 and a 2-fold change after Benjamini Hochberg multiple testing correction.
After 24 hr of treatment, a large number of genes were differentially regulated in response to each of the drugs, leading to upregulation of 300-500 genes and downregulation of 300-900 genes. The response to the three drugs was strikingly consistent; 245 genes were upregulated, and 312 were downregulated in all three treatments. The full data set is available online (NCBI GEO accession number GSE55979).
Expression changes were dominated by broad downregulation of basic cellular processes. Almost 70% of the genes encoding ribosomal proteins were downregulated, along with ATP synthase-related genes and the genes involved in cell division (ftsEQWXY). Also downregulated were nearly all of the NADHdehydrogenase complex I genes and genes of the mce1 and mce4 loci. thyX, which encodes the flavin-dependent alternate thymidylate synthase, was also modestly downregulated. Biosynthetic pathways for several amino acids were downregulated, including those involved in arginine, asparagine, and tryptophan biosynthesis. The set of downregulated genes also included seven methyltransferases known to be dependent on S-adenosylmethionine. These genes produce proteins used in a variety of metabolic pathways, including mycolic acid biosynthesis, RNA methylation, and production of phenolic glycolipids and pthiocerol dimycocerosates.
Against this backdrop of broad downregulation, the genes required for production of methionine and SAM were markedly upregulated ( Figure 5 ). The genes metA and metC were upregulated $15-fold, making them 2 of the 10 most strongly upregulated genes. Transcript levels of the methionine synthase gene metH and the SAM synthase gene metK increased $3-fold and nearly 2-fold, respectively. In contrast, genes associated with SAM utilization, including speE, mtn, and Rv2952, were among those repressed by antifolate treatment.
Supplementation with Serine/Methionine/Glycine, or with S-Adenosylmethionine, Rescues MTB from Antifolate Treatment Supplementation assays have long been used as tools to understand the effects of drug treatment and pathway inhibition in a variety of organisms (Daniel et al., 1947) . To probe the effects of folate pathway inhibition in MTB, we supplemented MTB cultures exposed to MIC levels of WR99210 or JSF-1187 with a variety of metabolites. Nucleosides, folic acid, leucovorin (5-formyl-tetrahydrofolate), and dTMP all failed to alter cell survival at concentrations up to 1 mM (data not shown). However, MTB lacks the annotated enzymes required to assimilate exogenous folate species (Fivian-Hughes et al., 2012) and is unlikely to efficiently transport phosphorylated nucleotide species across its thick and hydrophobic cell envelope.
The folate pathway is directly involved in the metabolism of three amino acids (Figure 1) . The serine hydroxymethyltransferases GlyA1 and GlyA2 use serine as the methyl donor to produce 5,10-methylene-tetrahydrofolate from tetrahydrofolate.
The reverse reaction transfers the methyl group from 5,10-methylenetetrahydrofolate to glycine, regenerating tetrahydrofolate. Another reduced folate cofactor, 5-methyltetrahydrofolate, is the methyl donor for the production of methionine from homocysteine. When cultures treated with MIC-level concentrations of WR99210 were grown in media supplemented with combined serine/methionine/glycine, cell growth was restored to approximately 75% of untreated cells ( Figure 6A) . A similar rescue from inhibition by DDS, SMX, WR99210, and JSF-1187 was observed when cells were grown in media containing all 20 L-amino acids (data not shown). However, when cultures were supplemented with a full amino acid mixture lacking serine, methionine, and glycine, there was no rescue from antifolate treatment ( Figure 6B ). There was also no rescue observed when treated cultures were grown on media containing D-amino acids ( Figure 6D ). As expected, supplementation with amino acids did not affect the outcome of treatment with isoniazid, an inhibitor of MTB cell wall biosynthesis (data not shown).
To test the hypothesis that antifolate treatment leads to a critical depletion of methionine derivatives, we also supplemented WR99210-treated cultures with S-adenosylmethionine (Figure 6C) . Supplementation with 80 mM SAM restored growth to approximately 50% that of untreated cultures, and growth was completely restored at 320 mM SAM. However, supplementation with methionine alone was unable to restore growth of cells treated with either WR99210 or JSF-1187 (data not shown). Altogether, these results suggest that disruption of the activated methyl cycle, rather than perturbation of folate-dependent amino acid levels, is the critical consequence of folate pathway disruption.
DISCUSSION
In an effort to identify antifolates with antitubercular properties, we explored methotrexate as a scaffold. Although methotrexate is inactive against whole-cell MTB, the methotrexate dialkyl ester analogs JSF-1187 and JSF-1183 exhibited MIC values between 200 and 600 nM against H37Rv (Table 1) . JSF-1187 was also tested and found active against a panel of MTB clinical isolates (Table S1 ). Although the mechanistic rationale for this increase in activity remains unresolved, a plausible explanation is that JSF-1183 and JSF-1187 benefit from improved target access. The alkylations afford more lipophilic molecules that may penetrate the hydrophobic mycobacterial cell wall better than methotrexate, which should form a dianion under assay conditions. These substitutions may also interfere with polyglutamylation of the molecule (Kwon et al., 2008) , although polyglutamylation of methotrexate has traditionally been associated with increased compound retention within the cell and increased affinity for DHFR (Liani et al., 2003) . Additionally, the mono-and di-esters do not display improved inhibition of DHFR but show a 4-to 25-fold decrease in DHFR enzyme inhibition in vitro (Table 1) . Similar trends were observed in inhibition studies using DHFR from rabbit, mouse, and Trypanosoma cruzi (Rosowsky et al., 1978) . A plausible scenario is that the methotrexate esters are sufficiently lipophilic and stable to penetrate the cell wall and then inhibit DHFR through a combination of the dialkyl ester, one or both mono-esters, and methotrexate.
Part of the rationale for studying antifolates in MTB is the wealth of information available about these molecules in other (Bushby, 1975) . However, we also show that the downstream consequences of folate inhibition in MTB differ substantially from the model developed primarily in Plasmodium and Escherichia coli. In particular, our data are not consistent with the ''thymineless death'' scenario that is the hallmark of antifolate treatment in other organisms (Ahmad et al., 1998; Hartman, 1993; Huennekens, 1996) .
Antifolates restrict cellular metabolism at several discrete steps (Figure 4) . Thymineless death describes a process in which antifolate-generated thymine starvation leads to increased rates of erroneous uridine incorporation into DNA and a subsequent accumulation of fatal single-and double-stranded breaks (Ahmad et al., 1998; Sangurdekar et al., 2011) . This idea was originally proposed after experiments in which bacteria treated with antifolates were rescued by thymine supplementation (Amyes and Smith, 1974) . Recent analyses support this concept, showing a rapid and significant drop in dTMP/thymidine/thymine levels in E. coli and Plasmodium falciparum following antifolate treatment (Kwon et al., 2010; Yeo et al., 1997) , although antifolates produce other metabolic disruptions as well. For example, in E. coli treated with antifolates, the glycine pool is depleted 10-fold within 5 min, and methionine levels decrease 85% within 30 min, whereas most amino acid levels gradually increase (Kwon et al., 2010) . In fact, when amino acid levels are low, E. coli is rescued from the bactericidal effects of thymineless death by a RelA-mediated stringent response (Kwon et al., 2010) . In MTB, however, the picture is quite different. We see little evidence to support the thymineless death scenario, and instead, our metabolomics, transcriptomics, and supplementation experiments are all consistent with a disruption in the activated methyl cycle.
Following antifolate treatment, our LC-MS experiments revealed limited disruption of MTB metabolite pools (Figures 3  and 4) . Even after 24 hr of treatment with WR99210 at $333 MIC, the putative thymine and glycine pools, as well as 80% of all compounds assayed, were unperturbed. Many of the metabolites that do change are linked to the activated methyl cycle. Comparing metabolite profiles following treatment with three antifolates revealed striking similarities, including substantial increases in AICAR and homocysteine and a drop in levels of SAM and methionine (Figure 4 ). These changes are accompanied by consistent shifts in expression of the relevant genes (Figure 5) . Exposure to the DHPS substrate and TB drug PAS yields a very comparable metabolic profile (Chakraborty et al., 2013) , suggesting that this pattern reflects a signature of folate pathway inhibition in MTB.
Supplementation experiments also produced a unique response in MTB. It is not surprising that supplementation with thymidine and dTMP failed to support bacterial growth after treatment with WR99210 and JSF-1187. MTB lacks an obvious homolog to thymidine kinase and thus cannot convert exogenous thymidine into the dTMP needed for DNA incorporation (Fivian-Hughes et al., 2012) . Additionally, the relatively impermeable mycobacterial cell wall is likely to limit the movement of dTMP into the cell, even when levels in the growth media are high (Nguyen and Thompson, 2006) . However, addition of SAM or a combination of serine, methionine, and glycine reversed the inhibitory effects of antifolates in MTB (Figure 6 ). In contrast, amino acid supplementation enhances antifolate killing in E. coli (Kwon et al., 2010) .
Altogether, our experiments suggest a model where methionine pools are depleted by antifolate treatment, whereas SAM pools are protected out to 4 hr of treatment. At some point, however, methionine levels stabilize, and other components of the activated methyl cycle are allowed to deplete. Continued flux through the activated methyl cycle is indicated by the drop in SAM and the increase in levels of putative S-ribosylhomocysteine (one of the end products of SAM demethylation) between 4 and 24 hr (Figure 3 ). We were unable to detect S-adenosylhomocysteine, a feedback inhibitor of many SAM-dependent methyltransferases (Reddy et al., 2008) , although it seems likely that it accumulates as well. In multiple cell lines, perturbation of the ratio of SAM and SAH, typically maintained at 10:1, leads to growth arrest (Reddy et al., 2008) . Whether such a mechanism exists in MTB and is induced following antifolate treatment remains to be seen.
Disruption of the activated methyl cycle should have multiple consequences. SAM is an integral donor of reactive methyl groups essential for cellular processes such as DNA methylation, MTB cells were treated with JSF-1183 or JSF-1187 at 100 mM for 24 hr, and results for core folate pathway metabolites were compared with those shown above for WR99210. Metabolite signal intensities were normalized to internal control metabolites. Results shown are on a log 2 scale and are representative of two independent experiments, with three technical replicates per experiment. Metabolite identities were confirmed using chemical standards demonstrating coelution with experimental samples, with the exception of AICAR.
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Folate Pathway Disruption in M. tuberculosis polyamine biosynthesis, and biotin production (Parveen and Cornell, 2011) . In MTB, the SAM-dependent methyltransferase Hma catalyzes the formation of both keto-and methoxy-mycolic acids (Boissier et al., 2006) ; another SAM-dependent methyltransferase, Rv2952, is responsible for the unique phthiocerol dimycocerosates and phenolic glycolipids found in the Beijing family of MTB strains (Huet et al., 2009) . SAM is also necessary for proper methylation of ribosomal RNAs in MTB (Kumar et al., 2011; Rahman et al., 2010) . Depletion of SAM pathway components likely disrupts these essential cellular reactions, as well as others that are not yet appreciated. Our current experiments cannot definitively exclude the possibility that starvation for dTMP plays a role in the death of MTB following antifolate treatment. Consistent with the thymineless death scenario, the MTB genes induced by exposure to antifolates include several associated with DNA repair (NCBI GEO accession number GSE55979). We also observe a 30-fold increase in dUMP after 24 hr of treatment with WR99210 at $333 MIC. Unfortunately, we were unable to measure dTMP or thymidine at any time point, although thymine levels remained unchanged. It should be noted, however, that MTB is unusual in possessing two thymidylate synthase enzymes (Figure 1 ). ThyA, a canonical thymidylate synthase, uses 5,10-methylene-tetrahydrofolate as both methyl donor and reductant. ThyX, a flavin-dependent thymidylate synthase, uses 5,10-methylene-tetrahydrofolate as methyl donor and FADH 2 as reductant (Fivian-Hughes et al., 2012) . This unique pairing may skew the response to folate pathway inhibition away from thymidylate starvation and toward the depletion of methionine derivatives.
Antifolates are an attractive class of inhibitors, whose potential for treating TB has yet to be realized. Increased understanding of the effects of folate pathway inhibition should allow rational design of better inhibitors and combinations. Although the folate pathway has been the subject of study for over 50 years, it is becoming clear that the established paradigms may not entirely apply to MTB, providing us with unique challenges to confront and unique opportunities to exploit.
SIGNIFICANCE
New agents to combat tuberculosis (TB) are badly needed, yet one of the world's most utilized drug targets-folate pathway inhibition-is not a part of front line TB
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Folate Pathway Disruption in M. tuberculosis chemotherapy, and widely used antifolates methotrexate and trimethoprim are inactive on M. tuberculosis (MTB) in culture. In this study, however, we identified antifolate variants of methotrexate with good activity versus MTB dihydrofolate reductase in vitro and potent activity against whole-cell MTB. Metabolomic analysis of antifolate-treated cultures revealed unique metabolic disruptions, including decreased pools of methionine and S-adenosylmethionine. Gene expression analysis highlighted altered regulation of genes involved in the biosynthesis and utilization of these two compounds. Supplementation with amino acids or S-adenosylmethionine was sufficient to rescue cultures from antifolate treatment. These data contrast substantially with the well-studied effects of folate pathway inhibition in other organisms. Instead of the ''thymineless death'' that characterizes antifolate addition in E. coli, Plasmodium, and other systems, these data suggest that MTB is vulnerable to a critical disruption of the reactions centered around S-adenosylmethionione, the activated methyl cycle. As a result, folate pathway inhibition in MTB may present novel opportunities and challenges for drug development.
EXPERIMENTAL PROCEDURES Bacterial Strains and Growth Conditions
Unless otherwise indicated, liquid cultures of mycobacteria were grown in 7H9 media supplemented with 0.05% Tween 80 and albumin, dextrose, and catalase (ADC; Becton Dickinson) or on Middlebrook 7H10 plates supplemented with oleic acid, ADC at 37 C. For metabolomic analysis cultures were grown on Middlebrook 7H10 plates supplemented with 5% bovine serum albumin, 2% dextrose, and 0.85% NaCl. Strains were grown to an optical density (OD 600 ) of approximately 1 and stored at À80 C in 15% glycerol. If needed, kanamycin was added at 30 or 50 mg/ml for mycobacteria and E. coli, respectively. H37Rv (American Type Culture Collection 25618) was used as the Mycobacterium tuberculosis wild-type strain, whereas E. coli DH5-a (Invitrogen) was used for cloning. H37Rv::pHigh22, bearing gfp driven by a strong 16S rRNA promoter, was used for all assays using a fluorescent read-out.
Construction of MTB Strains with Altered dfrA Expression
For the constitutively overexpressing construct pMRN1, PCR-amplified MTB dfrA sequence was cloned into the shuttle vector pJEB402 downstream of the mycobacterial constitutive promoter MOP (George et al., 1995) . This vector integrates into the MTB chromosome at the phage L5 attachment site (Lee and Hatfull, 1993) . DNA was isolated from E. coli transformants and introduced into MTB via electroporation as previously described (Park et al., 2003; Wards and Collins, 1996) . Kanamycin was used to select for transformants, and qRT-PCR was used to quantify the level of dfrA overexpression. Construction of the strain H37Rv:dfrA-TetON used for underexpression in the absence of tetracycline was described previously (Kumar et al., 2012) .
Expression and Purification of MTB-DHFR Competent E. coli BL21 (DE3) cells (Novagen) were transformed with recombinant plasmid containing dfrA gene and grown at 37 C to OD 600 of 0.7 in LB medium containing 70 mg/ml of kanamycin. The cells were cooled to 20 C and equilibrated for an hour, and protein expression was induced by the addition of 0.8 mM IPTG. After an overnight induction, the cells were spun down at 4,000 rpm. The pellet was resuspended in the buffer (20 mM triethanolamine [TEA], 30 mM imidazole, 50 mM KCl [pH 7.8]) containing protease inhibitor cocktail (Novagen), 20 mg of egg white lysozyme (Sigma), and 5 of mg bovine pancreas DNase I. The resuspended cells were disrupted by cell lysis machine and were spun down at 16,000 rpm for 50 min to remove the cell debris. The supernatant, filtered through 0.22 mm, was applied to a 15 ml column of high performance HisTrap column (GE Healthcare) pre-equilibrated by the loading buffer (20 mM TEA, 30 mM imidazole, 300 mM KCl [pH 7.8]). The cell-loaded column was washed with extensive amounts of the loading buffer and then eluted with a linear gradient (350 ml) from 0% to 100% of elution buffer (20 mM TEA, 500 mM imidazole, 300 mM KCl [pH 7.8]). The pure DHFR-containing fractions were pooled and concentrated down to 4 ml and treated with 30 ml of thrombin (Novagen) at 16 C for 3 days. The cleaved protein was passed through a 5 ml HisTrap HP column (GE Healthcare) preequilibrated with the loading buffer. The unbound protein was collected, dialyzed against 4 l of dialysis buffer (25 mM potassium phosphate, 50 mM KCl, 0.1 mM EDTA, 5% glycerol [pH 7.2]) for 6 hr, and concentrated down to 15 mg/ml.
In Vitro Assay for MTB-DHFR
The enzyme assay for Mtb DHFR was performed in 100 mM HEPES, 50 mM KCl (pH 7.0) at 25 C. The absorbance decrease at 340 nm, representing the 
Preparation of Test Compounds
WR99210 was kindly provided by Jacobus Pharmaceuticals. Synthesized compounds are designated as JSF-####. Trimetrexate, trimethoprim, methotrexate, piritrexim, sulfamethoxazole, and dapsone were purchased from commercial sources. All compounds were dissolved in DMSO. All drug aliquots were stored at À20 C until immediately before use.
Assessment of Antitubercular Activity MTB cultures were grown to mid-log phase and then diluted to a calculated starting OD 600 of 0.001 and aliquoted into 96-well plates. Test compounds in DMSO were added at 1% of total volume. A 1:100 dilution was used to determine the MIC cutoff for each assay. Plates were incubated for 7 days at 37 C.
The BacTiter-Glo Microbial Cell Viability Kit (Promega) was used to measure intracellular ATP levels as a proxy for cell survival and growth. Cultures were incubated with reconstituted, room temperature BacTiter-Glo Reagent for 10-20 min prior to luminescence quantification by a FLUOStar Omega plate reader. MICs were confirmed with an MTB H37Rv strain that constitutively expresses GFP. Growth was monitored by quantitating fluorescence (excitation: 485 nm; emission: 520 nm) using the FLUOStar Omega plate reader.
Metabolomic Sample Preparation
For metabolomic analysis samples were prepared according to previously published procedures (de Carvalho et al., 2010a) . In short, MTB was grown to mid-log phase and then diluted to an OD 600 of 0.1. A 1 ml culture was then inoculated onto 22 mm 0.2 mm nitrocellulose filters (Millipore) using vacuum filtration, placed on 7H10+ADN plates, and incubated at 37 C. On day 5 postinoculation, the MTB-laden filters were transferred to plates containing appropriate concentrations of drug. At appropriate times, cell metabolism was quenched by freezing MTB-laden filters in À40 C acetonitrile:methanol:H 2 O (40:40:20). Cells were lysed by bead beating, with cooling on ice between steps, and the extracts purified by centrifugation and 0.22 mm filtration. Each technical replicate combined the biomass from eight nitrocellulose filters, and an experiment included three technical replicates for every time point. Each experiment was performed twice.
Liquid Chromatography-Mass Spectrometry A Cogent Diamond Hydride Type C column (Gradient 3) was used to separate metabolites as described previously (Pesek et al., 2009 ). An Agilent Accurate Mass 6220 TOF was coupled to an Agilent 1200 liquid chromatography system for analysis. This configuration achieves mass errors of approximately 5 ppm, mass resolution ranging from 10,000 to 25,000 (over m/z 121-955), and a 5 log 10 dynamic range. Metabolite identities were queried using a mass tolerance of <0.005 Da. Signal intensities were normalized within experiments using acetyldiaminopimelate, acetylaminoadipate, indolepyruvate, aminooxopimelate, and triose phosphate, 5 of the 74 metabolites whose abundance was unaffected by WR99210. Putative metabolite identities were based on accurate mass (m/z) and chromatographic retention time matching. Metabolite identities were verified by coelution with a chemical standard and metabolite concentrations were calculated using the method of standard addition, where available.
RNA Preparation
RNA was isolated as described previously (Rustad et al., 2008) . Briefly, pellets were condensed from 40 ml of culture (OD 600 0.1) and then resuspended in TRIzol. The cells were lysed by bead beating, with cooling on ice between steps. The cell lysates were then centrifuged, and the supernatant was transferred to a tube with Heavy Phase Lock Gel (Eppendorf North America) and chloroform, inverted for 2 min, and then centrifuged at max speed for 5 min. The aqueous phase was precipitated with isopranol and high salt solution (0.8 M sodium citrate, 1.2 M NaCl). RNA was purified using an RNeasy kit (Qiagen).
Microarray Analysis
RNA was converted to CyDye-labeled cDNA probes as described previously (Rustad et al., 2008) . For all experiments described here, 2 mg of total RNA was used to generate probes. Sets of fluorescent probes were then hybridized as previously described (Minch et al., 2012) . Briefly, the arrays were custom NimbleGen tiling arrays consisting of 135,000 probes spaced at $100 bp intervals around the MTB H37Rv genome (NCBI GEO accession number GPL14896). Three biological replicate experiments were used for each drug at each time point. Arrays were scanned, and spots were quantified using a Genepix 4000B scanner with GenePix 6.0 software. These data were exported to NimbleScan for mask alignment and ArrayStar for robust multichip average (Bolstad et al., 2003) normalization and statistical analysis (NCBI GEO accession number GSE55979). Altered gene expression was considered significant if it produced a moderated t test p < 0.01 and a log 2 change R 1 after Benjamini Hochberg multiple testing correction.
Supplementation Assays
Supplemented stock media was made by adding filter sterilized metabolites to 7H9 for a final concentration of 2 mM for each individual metabolite. MTB cultures constitutively expressing GFP as a reporter for growth were grown to mid-log phase in 7H9 and then diluted to a calculated starting OD 600 of 0.001 in supplemented media and dispensed into 96-well plates. Test compounds in DMSO were added at 1% of total volume. Cells diluted 1:100 at day 0, without drug treatment, were used to determine the MIC cutoff for each assay. Plates were incubated for 7 days at 37 C, with growth monitored by fluorescence as described above. All results were confirmed by optical density readings.
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